Daily administration of SMN2 splicing modifier SMN-C3 at a suboptimal dose in SMN∆7 mice induces a milder SMA phenotype (Feng et al, 2016) with low body weight and a median life span of 28 d; however, the required daily intraperitoneal injection and oral gavage are a significant burden to the neonatal mice. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.